For example, trastuzumab is only given to the subgroup (stratum) of breast cancer patients who are human epidermal growth factor receptor 2 (HER‐2) positive, as it is known to lock on to the HER‐2 protein, block the receptor and stop the cells from dividing and growing 2. This evidence concerns the gene ERBB2 and breast cancer.